Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.

ABSTRACT:

Objective

Evaluate the human abuse potential, pharmacokinetics, pharmacodynamics, and safety of NKTR-181, a novel mu-opioid agonist molecule, relative to oxycodone.

Design

This randomized, single-center, double-blind, active- and placebo-controlled five-period crossover study enrolled healthy, adult, non-physically dependent recreational opioid users.

Setting

Inpatient clinical research site.

Subjects

Forty-two randomized subjects (73.8% male, 81% white, mean age = 25 years).

Methods

The primary objective was to evaluate single orally administered 100, 200, and 400 mg NKTR-181 doses in solution compared with 40 mg oxycodone and placebo solutions using the Drug Liking visual analog scale. Secondary measures included the Drug Effects Questionnaire, Addicti

SUBMITTER: Webster L 

PROVIDER: S-EPMC5914314 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature